MacroGenics says MGC026 shows 27% response rate in SCCHN, advancing to front-line pembrolizumab combo trial

MacroGenics announced Phase 1 data for MGC026 showing a 27% response rate in squamous cell carcinoma of the head and neck (SCCHN) with durable tumor activity, and said the drug is advancing toward a front-line pembrolizumab combination trial.

Detected & updated continuously · Source: Nebula